<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52680">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420379</url>
  </required_header>
  <id_info>
    <org_study_id>4658-203</org_study_id>
    <nct_id>NCT02420379</nct_id>
  </id_info>
  <brief_title>Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy</brief_title>
  <official_title>An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to assess the safety, tolerability, efficacy and
      pharmacokinetics of eteplirsen in patients with early stage Duchenne muscular dystrophy
      (DMD) who are amenable to exon 51 skipping.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety, including adverse event monitoring and routine laboratory assessments, will be
      followed on an ongoing basis for all patients.

      Clinical efficacy, including functional tests and MRI, will be assessed at regularly
      scheduled study visits. Patients will undergo one baseline and one follow-up muscle biopsy.

      Population and serial PK will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment emergent adverse events</measure>
    <time_frame>96 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in percent of dystrophin-positive skeletal muscle fibers</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug concentration in plasma</measure>
    <time_frame>96 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Duchenne Muscular Dystrophy (DMD)</condition>
  <arm_group>
    <arm_group_label>Open-Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
*Enrollment in this arm is complete.*</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
*Enrollment in this arm is ongoing.*</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eteplirsen</intervention_name>
    <description>Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.</description>
    <arm_group_label>Open-Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 4-6 years of age.

          -  Diagnosis of DMD, genotypically confirmed.

          -  Stable dose of oral corticosteroids for at least 12 weeks or has not received
             corticosteroids for at least 12 weeks.

          -  Intact right and left biceps muscles or two alternative upper arm muscle groups.

          -  Parent that is willing to provide consent and comply with study procedures.

        Exclusion Criteria:

          -  Use of any pharmacologic treatment (other than corticosteroids) within 12 weeks that
             may have an effect on muscle strength or function (e.g., growth hormone, anabolic
             steroids).

          -  Previous or current treatment with any other experimental treatments within 12 weeks
             or participation in any other clinical trial within 6 months.

          -  Major surgery within 3 months prior to the first dose of study drug, or planned
             surgery during this study which would interfere with the ability to perform study
             activities.

          -  Presence of other clinically significant illness.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Duda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward M. Kaye, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Boniface</last_name>
    <email>trialinfo@sarepta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neuromuscular Research Center of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Osgood, DPM, MPH</last_name>
      <phone>480-314-1007</phone>
      <phone_ext>6</phone_ext>
      <email>nrcresearch@nrcaz.com</email>
    </contact>
    <contact_backup>
      <last_name>Mark Gonzalez</last_name>
      <phone>480-314-1007</phone>
      <email>markgonzalez@nrcaz.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kumaraswamy Sivakumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bonitati</last_name>
      <phone>310-825-3264</phone>
      <email>MBonitati@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Perry Shieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Goude</last_name>
      <phone>916-734-0384</phone>
      <email>emgoude@ucdavis.edu:</email>
    </contact>
    <investigator>
      <last_name>Craig McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bona Purse</last_name>
      <email>bonap@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida, Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LeeAnn Lawson</last_name>
      <phone>352-273-7762</phone>
      <email>LLawson@peds.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Barry Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saadia Khizer</last_name>
      <email>Saadia.Khizer@choa.org</email>
    </contact>
    <investigator>
      <last_name>Han Phan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Stephan</last_name>
      <phone>319-356-2673</phone>
      <email>carrie-stephan@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Christenson</last_name>
      <phone>314-362-6991</phone>
      <email>christensont@neuro.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Krystal Reese</last_name>
      <phone>314-362-1146</phone>
      <email>reesek@neuro.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anne M Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Petek</last_name>
      <phone>614-722-2715</phone>
      <email>Christopher.Petek@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jerry Mendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Rother</last_name>
      <phone>971-544-3377</phone>
      <email>RWR@shcc.org</email>
    </contact>
    <investigator>
      <last_name>Erika Finanger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Bergman</last_name>
      <phone>267-425-2111</phone>
      <email>BERGMAN@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Gihan Tennekoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Christensen</last_name>
      <phone>206-884-2756</phone>
      <email>ana.christensen@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Susan Apkon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 3, 2017</lastchanged_date>
  <firstreceived_date>April 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>eteplirsen</keyword>
  <keyword>Dystrophin</keyword>
  <keyword>exon 51</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
